axelopran Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Axelopran is a drug which is under development by Theravance Biopharma and licensed to Glycyx for all indications. It acts as a peripherally acting μ-opioid receptor antagonist and also acts on κ-, and δ-opioid receptors, with similar affinity for the μ- and κ-opioid receptors and about an order of magnitude lower affinity for the δ-opioid receptor. Recent data suggests that μ-opioid antagonists have a direct effect on overall survival in patients with advanced cancer.   Wikipedia

Chemistry

  • SMILES: NC(=O)c1cccc(c1)[C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC4CCCCC4)C(=O)[C@@H](O)CO
  • InChIKey: ATLYLVPZNWDJBW-KIHHCIJBSA-N
  • Mol. Mass: 457.62
  • ALogP: 2.26
  • ChEMBL Molecule:
    axelopran  
More Chemistry

Pharmacology

Alternative names

3-(8-(2-(cyclohexylmethyl(2,3-dihydroxypropionyl)amino)ethyl)-8-azabicyclo(3.2.1)oct-3-yl)benzamide | 3-endo-(8-(2-(cyclohexylmethyl-((s)-2,3-dihydroxypropionyl)amino)ethyl)-8-azabicyclo(3.2.1)oct-3-yl)benzamide | axelopran | td-1211

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Constipation (Phase 1)

Healthy Volunteers (Phase 1/Phase 2)

Opioid-Induced Constipation (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue